NCT02379390 - Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2015

Primary Completion Date

May 10, 2018

Study Completion Date

May 10, 2018

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

Cabazitaxel XRP6258

DRUG

Ezalutamide

DRUG

Abiraterone acetate

DRUG

Prednisone

Trial Locations (24)

20850

Investigational Site Number 840012, Rockville

29572

Investigational Site Number 840016, Myrtle Beach

33486

Investigational Site Number 840002, Boca Raton

33805

Investigational Site Number 840027, Lakeland

34952

Investigational Site Number 840006, Port Saint Lucie

35661

Investigational Site Number 840030, Muscle Shoals

44718

Investigational Site Number 840022, Canton

61350

Investigational Site Number 840015, Ottawa

68198

Investigational Site Number 840026, Omaha

70006

Investigational Site Number 840017, Metairie

70433

Investigational Site Number 840001, Covington

92801

Investigational Site Number 840028, Anaheim

95817

Investigational Site Number 840004, Sacramento

99508

Investigational Site Number 840024, Anchorage

T6G 1Z2

Investigational Site Number 124003, Edmonton

J4V2H1

Investigational Site Number 124010, Greenfield Park

L8V 5C2

Investigational Site Number 124005, Hamilton

N6A 4L6

Investigational Site Number 124004, London

H2L 4M1

Investigational Site Number 124002, Montreal

H2W1S6

Investigational Site Number 124006, Montreal

K1H8L6

Investigational Site Number 124007, Ottawa

G1R 2J6

Investigational Site Number 124009, Québec

S7N4H4

Investigational Site Number 124008, Saskatoon

N5Z4E6

Investigational Site Number 124001, Vancouver